Biomay AG

Biomay Announces its Successful Support of Approval of First CRISPR/Cas9-based Therapy


Biomay, a biotech contract development and manufacturing organization based in Vienna, Austria, announces successful completion of an FDA inspection qualifying Biomay as a cGMP manufacturer and supplier of recombinant nuclease Cas9 for use in gene editing therapies.

Biomay AG is manufacturing Cas9 nuclease for first approved CRISPR-based therapy
Biomay AG is manufacturing Cas9 nuclease for first approved CRISPR-based therapy

As part of an ongoing cooperation initially dating back to 2017, Biomay has manufactured and delivered Cas9 in the course of Vertex´and CRISPR Therapeutics’ clinical development of exagamglogene autotemcel (CASGEVY®), a gene edited therapy for the treatment of sickle cell disease (SCD) and transfusion dependent beta-thalassemia (TDT). CASGEVY® is the first CRISPR/Cas9-based therapy to receive marketing approval from the FDA, MHRA and positive CHMP opinion from the EMA.

Biomay has developed and validated a Cas9 manufacturing process together with the associated analytical quality control methods. This included the construction of an E. coli expression system, GMP cell banking, upstream and downstream development, as well as the establishment of a comprehensive set of analytical quality control methods. An in-depth product and process characterization program, analytical method validation, as well as full manufacturing process validation have been performed. Recently, the U.S. FDA completed a Pre-License Inspection of Biomay´s facilities and systems in the context of Vertex’s Biologics License Applications (BLAs) for exagamglogene autotemcel (CASGEVY®).

Biomay´s Chief Executive Officer, Hans Huber, PhD, stated: “We are pleased that Biomay has successfully completed the inspection by the FDA. This inspection represents a significant milestone for Biomay. It underscores our unwavering commitment to quality, continuous improvement, and the highest standards in all our operations.

Angela Neubauer, SVP Client Business at Biomay added: “We are very excited about the news of the first CRISPR/Cas9-based gene editing therapy entering the market. We are proud of having successfully supported our clients in reaching that goal, for the benefits of numerous patients.”


Dr. Angela Neubauer, SVP Client Business; Tel.: +43-1-7966296-100, E-Mail: / Biomay AG, Ada Lovelace-Str. 2, A-1220 Vienna, Austria


Biomay AG is manufacturing Cas9 nuclease for first approved CRISPR-based therapy
Biomay AG is manufacturing Cas9 nuclease for first approved CRISPR-based therapy

About Biomay

Biomay AG is a privately owned and fully integrated Contract Development and Manufacturing Organization (CDMO) based in Vienna, Austria. Founded in 1984, the expression of recombinant proteins by utilizing E. coli has been Biomay´s business focus yet from its beginning. Today, Biomay offers cGMP services for manufacturing of therapeutic proteins, plasmid DNA (pDNA) and messenger RNA (mRNA). The company´s scope of services comprise process and analytical development, cell banking, cGMP manufacturing of drug substance and aseptic filling of drug product.

Subscribe to releases from Biomay AG

Subscribe to all the latest releases from Biomay AG by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Biomay AG

Biomay Cooperates with BioNTech to Supply DNA Template for COVID-19 mRNA Vaccine18.5.2021 09:45:00 CEST | Pressemeddelelse

Vienna, May 17, 2021 Biomay, a Vienna based biotech manufacturer, today announced their partnership with BioNTech SE to support the supply chain for manufacturing of the Pfizer-BioNTech COVID-19 mRNA vaccine. Biomay is one of the manufacturers supplying BioNTech with the DNA template for the in-vitro transcription of their mRNA active ingredient. The manufacturing agreement was initiated during the clinical development phase of the vaccine in Q1/2020. In the meantime, Biomay has become a formally qualified supplier for BioNTech. The scope of services includes process and analytical development, followed by GMP preparation of the cell bank, manufacturing of circular DNA plasmid and finally preparation of the linear DNA template. In 2021, Biomay has produced and delivered multiple batches of released DNA template and supported the mRNA vaccine production thanks to this important manufacturing component, and the company will continue to do so throughout the year. Hans Huber, Chief Executi

Construction Project of Biomay’s Manufacturing Facility Fully on Schedule14.5.2021 11:40:42 CEST | Press release

Construction work on Biomay’s new headquarters and biotech manufacturing facility in Aspern Seestadt, Vienna, is progressing on schedule. Seven months after the groundbreaking ceremony in September 2020, the building shell has now been completed. Ongoing activities are currently focused on the interior works and the installation of the complex heat, ventilation and air conditioning (HVAC) and utility systems.

HiddenA line styled icon from Orion Icon Library.Eye